 - may have received pemetrexed or docetaxel from previous Phase 3 trial A8081007 and discontinued treatment due to Response Evaluation Criterion in Solid Tumors RECIST-defined progression. or, once the primary endpoint of Study A8081007 has been analyzed and the results made available, at any time without RECIST-defined progression. 